NYSE: ABT

Abbott Laboratories (ABT) Stock Analysis & Forecast

Nov 13 close

$108.52+1.27 (+1.2%)

Gekko Brief

AI summaryNov 13 close

Abbott's week centers on Q3 2026 results and a major strategic shift: the company reported sales up 14.5% and adjusted EPS rising 9.2%, though it slightly missed consensus EPS estimates, with adjusted EPS at $1.42 against a $1.42 estimate. Alongside earnings, Abbott outlined plans to spin off its global Nutrition business, which generates approximately $8.5 billion in annual sales, by the end of 2027 to sharpen focus on its medical devices, diagnostics, and medicines segments. Separately, the company's UltiSynq defibrillation lead received FDA approval and a CE mark, expanding its cardiac rhythm management portfolio. Shares also saw some choppiness, falling 1.87% to $107.25 on Thursday and 1.06% to $109.29 on Wednesday, marking a third straight day of losses during that stretch.

Abbott closed at $108.52, up 1.2%, sitting above both its 50-day average of $103.91 and 200-day average of $101.56, with the 50-day above the 200-day. The GekkoIndex reads 53.5, placing it in the Neutral zone. Price remains 12.3% below Gekko Fair Value of $123.74.

Over the next 20 trading days, the next earnings date falls outside that window, set for 28 January 2027. Congressional activity over the past 90 days shows 2 buys and 0 sells, with one billionaire holder noted. Seasonality over 5 years shows the next 20 trading days averaging a 4.3% return, with gains in 3 of those years. Analyst sentiment includes 16 buy ratings against 2 holds and 0 sells among 18 firms, with a consensus target of $118.91.

Written by AI from the Nov 13, 2026 close and checked automatically against the figures on this page.

Abbott Laboratories price vs fair value

$121.31$108.52Nov ’25May ’26Nov ’26
Close $108.52200-day averageGekko Fair Value $121.31

Abbott Laboratories quick facts

Market cap
$188.0B
P/E ratio
40
Forward P/E
18.5
EPS, TTM
$2.68
Revenue, TTM
$48.23B
Profit margin
9.8%
Dividend yield
2.31%
Beta
0.54
Volume
6.18M avg 9.33M
1-year return
−15.8%
Typical daily move
±2.8%
Typical 20-day move
±4.4%
50-day average
$103.91
200-day average
$101.56
Next earnings
Jan 28 before open
Shares outstanding
1.73B
52-week range
$81.97$132.03

Abbott Laboratories swing-trade checklist

Abbott Laboratories scores 5 supportive, 1 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

5 supportive1 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $108.52 is above the 50-day ($103.91) and 200-day ($101.56) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    53.5, Neutral

    Reading 53.5 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    10.5% below

    Price is 10.5% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: Congress 2 buys / 0 sales.

    See smart money
  • Earnings risksupportive

    Reports in 74 days

    Next report Jan 28, 2027, 74 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +3.9% on average

    From this point in the calendar, the next 20 trading days averaged +3.9% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Abbott Laboratories stock chart and price history

Abbott Laboratories closed at $108.52 on Nov 13, 2026, −15.8% over the past year, inside a 52-week range of $81.97 to $132.03.

Close50-day average200-day averageVolume
Abbott Laboratories share price, past year, with 50-day and 200-day moving averages and volume$80$90$100$120$130DecJan 2026FebMarAprMayJunJulAugSepOctNov108.52

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+3.7%
3 months
−1.7%
6 months
+28.5%
1 year
−15.8%
The full ABT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ABT in Gekko

Follow Abbott Laboratories through every session

Put ABT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track ABT in GekkoFree for 7 days. No credit card required.

About Abbott Laboratories

Abbott Laboratories works across healthcare, researching, making and distributing a broad range of health products worldwide through its own operations and related entities. It is organized into four areas: established pharmaceuticals, diagnostics, nutrition and medical devices. Its pharmaceutical line includes generic medicines for conditions such as digestive disorders, hormone-related issues, cholesterol and blood pressure management, thyroid problems, vertigo, pain and migraine, along with an anti-infective, flu vaccines and treatments that support colon function.

The diagnostics business supplies laboratory systems for immunoassay, chemistry, hematology and transfusion testing, along with molecular platforms that process DNA and RNA and identify infectious agents. It also makes point-of-care devices, testing cartridges, rapid tests for pathogens including HIV, SARS-CoV-2, influenza and RSV, plus tools for cardiometabolic and substance testing, remote monitoring, consumer self-tests and lab automation software. The nutrition segment produces formulas for infants and adults, while the medical devices unit makes cardiovascular products such as rhythm management and structural heart devices, along with diabetes care tools and neuromodulation devices for pain and movement disorders.

Abbott Laboratories was founded in 1888 and is headquartered in North Chicago, Illinois. Its shares are listed on the NYSE under the ticker ABT.

Listed
NYSE
Sector
Health technology
Industry
Medical specialties
Website
abbott.com

Abbott Laboratories GekkoIndex: the smart money zone

Abbott Laboratories’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.5, in the Neutral zone, up 4.5 points over five sessions.

010053.5Neutral

Up 4.5 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying320.0%−0.2%−1.5%−4.5%
Accumulation268+0.1%+0.1%+0.6%+1.2%
Neutral (current zone)371+0.1%0.0%−0.2%−0.5%
Distribution26−0.2%−0.7%−0.3%−4.3%
Selling5Too few readings yet

Average ABT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the ABT price, zone by zone.Track ABT in Gekko

Is Abbott Laboratories stock overvalued? Gekko Fair Value

Abbott Laboratories trades 10.5% below Gekko Fair Value of $121.31, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Abbott Laboratories shares are worth, recalculated every trading day.

$121.31

Gekko Fair Value, Nov 14, 2026

10.5% Undervalued

At the end of Aug 2026 the price was 12.6% below the estimate.

Gekko Fair ValueShare price, month end
$121$109Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open ABT in Gekko

Abbott Laboratories insider and Congress trading

No open-market insider purchases were filed for Abbott Laboratories, and members of Congress disclosed 2 purchases and 0 sales, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for ABT in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every ABT insider filing, plotted on the chart in Gekko.Open ABT in Gekko

Congress trades last 90 days

2trades disclosed: 2 purchases and 0 sales.

MemberTypeAmountDisclosed
Gilbert Cisneros
House, CA, purchase
Purchase$1,001 - $15,000Oct 12
traded Sep 18
Ro Khanna
House, CA, purchase
Purchase$1,001 - $15,000Oct 9
traded Sep 4

From congressional disclosures, which report amounts as ranges.

Buybacks

Abbott Laboratories has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$11.00M
As a share of market cap
0.01%
Trailing four quarters
$1.54B

From company filings.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds ABT.

0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Abbott Laboratories earnings: next date and track record

Abbott Laboratories reports on Jan 28, 2027, before the open (74 days away), and beat the EPS estimate in 3 of its last 8 reports.

3 of 8reports beat the EPS estimate
±6%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+5.5%Jan ’25+3.8%Apr ’25−6.1%Jul ’25−4.2%Oct ’25−11.0%Jan ’26−4.7%Apr ’26+12.8%Jul ’26+0.1%Oct ’26

Last earnings call, Oct 21, 2026 AI summary

What they said
Abbott announced Q3 2026 results alongside a major strategic initiative to spin off its nutrition business into an independent publicly traded company. The nutrition segment generates approximately $8.5 billion in annual sales with 16,000 employees across 14 manufacturing sites, housing brands including Similac, Ensure, Glucerna, and Pedialyte. Management cited evolving consumer-driven market dynamics as justification for the separation, believing both entities will achieve greater value independently. Daniel Salvadori will lead the new nutrition company as CEO.
Guidance
No specific financial guidance or revenue/earnings targets were provided in this excerpt. Management expects the new nutrition company to qualify for S&P 500 inclusion based on its scale and financial profile. Further details on separation timeline and financial targets are anticipated.
ReportedEPSSurpriseRevenueSurpriseMove
Oct 21, 2026$1.42
est $1.42
0.0%$13.01B
est $12.99B
+0.2%+0.1%
Jul 16, 2026$1.31
est $1.28
+2.3%$12.59B
est $12.52B
+0.6%+12.8%
Apr 16, 2026$1.15
est $1.15
0.0%——−4.7%
Jan 22, 2026$1.50
est $1.49
+0.7%$11.46B
est $11.80B
−2.9%−11.0%
Oct 15, 2025$1.30
est $1.30
0.0%$11.37B
est $11.39B
−0.2%−4.2%
Jul 17, 2025$1.26
est $1.26
0.0%$11.14B
est $11.09B
+0.5%−6.1%
Apr 16, 2025$1.09
est $1.07
+1.9%$10.36B
est $10.41B
−0.5%+3.8%
Jan 22, 2025$1.34
est $1.34
0.0%$10.97B
est $11.03B
−0.5%+5.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Abbott Laboratories stock forecast and analyst price targets

Analysts’ average 12-month price target for Abbott Laboratories is $118.91, +9.6% from the last close, from 18 firms rating the stock in the last 90 days.

$118.91consensus 12-month target, +9.6% from the last close
Low $115High $135
Buy16
Hold2
Sell0

Each firm’s latest rating in the last 90 days: 18 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 9Bank of America SecuritiesBuy, maintained$125+15.2%
Nov 2Piper SandlerBuy, maintained$118+8.7%
Oct 30Bank of America SecuritiesBuy, reiterated$115+6.0%
Oct 27Argus ResearchHold, downgraded——
Oct 23Wells FargoBuy, maintained$120+10.6%
−0.2%average 20-day move after past Neutral readings
+3.9%average move over the next 20 trading days in the last 5 years
±2.8%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Abbott Laboratories seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Abbott Laboratories averaged +3.9% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

+2.7%2021+9.3%2022+10.5%2023−1.4%2024−1.6%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+0.4%3 of 5
Next 10 trading days+1.5%3 of 5
Next 15 trading days+1.1%3 of 5
Next 20 trading days+3.9%3 of 5
Next 30 trading days+4.8%3 of 5

For scale, ABT’s typical 20-trading-day move in either direction is about 4.4%.

Abbott Laboratories market cap and key statistics

Abbott Laboratories’s market cap is $188.0B, with a P/E ratio of 40 and revenue of $48.23B over the last twelve months.

Valuation

Market cap
$188.0B
P/E ratio
40
Forward P/E
18.5
EPS, TTM
$2.68
Gekko Fair Value
$121.31

Trading

Volume
6.18M
Avg volume, 20 days
9.33M
52-week high
$132.03
52-week low
$81.97
Shares outstanding
1.73B

Financials

Revenue, TTM
$48.23B
Profit margin
9.8%
Return on equity
9.1%
Quarterly earnings growth, YoY
−43.6%

Risk and income

Beta
0.54
Typical daily move
±2.8%
Typical 20-day move
±4.4%
Dividend yield
2.31%

Abbott Laboratories stock news this week

Coverage of Abbott Laboratories this week reads positive: 7 positive, 5 neutral and 5 negative headlines.

News sentiment positive

Abbott Laboratories peers

Abbott Laboratories’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.2%Neutral15.0% above
DHRDanaher0.0%Neutral4.7% above
ISRGIntuitive Surgical0.0%Neutral17.5% above
MDTMedtronic+0.7%Neutral14.2% below
SYKStryker−2.0%Neutral0.1% below
BSXBoston Scientific−0.8%Neutral25.8% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

Abbott Laboratories stock FAQ

What is Abbott Laboratories’s market cap?

Abbott Laboratories’s market cap is $188.0B at the Nov 13, 2026 close of $108.52, with 1.73B shares outstanding. The shares trade on a P/E ratio of 40.

What is the Abbott Laboratories stock forecast?

The consensus analyst 12-month price target for Abbott Laboratories is $118.91, +9.6% from the last close. Of the 18 firms that rated the stock in the last 90 days, 16 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Abbott Laboratories stock overvalued or undervalued?

On Gekko’s estimate Abbott Laboratories is undervalued: the Nov 13, 2026 close of $108.52 is 10.5% below Gekko Fair Value of $121.31. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Abbott Laboratories report earnings next?

Abbott Laboratories is expected to report on Jan 28, 2027, before the market opens (74 days away). Analysts expect earnings of $1.64 per share on revenue of $13.21B. Abbott Laboratories beat the earnings estimate in 3 of its last 8 reports, moving 6% on average across the report.

What is Abbott Laboratories’s 52-week high and low?

Abbott Laboratories’s 52-week high is $132.03 and its 52-week low is $81.97; it closed at $108.52 on Nov 13, 2026, −15.8% over the past year. Over the last five years the shares peaked at $142.60 on Dec 27, 2021.

Is Abbott Laboratories stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (trend, fair value, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Abbott Laboratories the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.